Gene therapy for rhesus monkeys heterozygous for LDL receptor deficiency by balloon catheter hepatic delivery of helper-dependent adenoviral vector

Gene Therapy

Volumn 22, Issue 1, 2015, Pages 87-95

  Oka, K ^a   Mullins, C E ^a   Kushwaha, R S ^b   Leen, A M ^a   Chan, L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BALLOON CATHETER; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HELPER DEPENDENT ADENOVIRUS; HEPATIC ARTERY; MALE; NONHUMAN; RHESUS MONKEY; TURNOVER TIME; VEIN OCCLUSION; VIRAL GENE THERAPY; VIRUS PARTICLE; ADENOVIRIDAE; ANIMAL; BALLOON OCCLUSION; DEFICIENCY; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; INTRAARTERIAL DRUG ADMINISTRATION; LIVER; METABOLISM; PATHOPHYSIOLOGY; VASCULARIZATION;

MACACA MULATTA; PRIMATES;

ADENOVIRIDAE; ANIMALS; BALLOON OCCLUSION; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HEPATIC ARTERY; HYPERLIPOPROTEINEMIA TYPE II; INJECTIONS, INTRA-ARTERIAL; LIVER; MACACA MULATTA; MALE; RECEPTORS, LDL; TRANSDUCTION, GENETIC;

EID: 84920538278     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.85     Document Type: Article

References (49)

1. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111: 1795-1803.
2. Hovingh GK, Davidson MH, Kastelein JJ, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013; 34: 962-971.
3. Chowdhury JR, Grossman M, Gupta S, Chowdhury NR, Baker Jr JR, Wilson JM. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 1991; 254: 1802-1805.
4. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994; 6: 335-341.
5. Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJ 3rd et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1: 1148-1154.
6. Bilheimer DW, Goldstein JL, Grundy SM, Brown MS. Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J Clin Invest 1975; 56: 1420-1430.
7. Brown MS, Goldstein JL, Havel RJ, Steinberg D. Gene therapy for cholesterol. Nat Genet 1994; 7: 349-350.
8. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 2001; 98: 13282-13287.
9. Nomura S, Merched A, Nour E, Dieker C, Oka K, Chan L. Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Therapy 2004; 11: 1540-1548.
10. Li R, Chao H, Ko KWS, Cormier S, Dieker C, Nour EA et al. Gene therapy targeting LDL cholesterol but not HDL cholesterol induces regression of advanced atherosclerosis in a mouse model of familial hypercholesterolemia. J Genet Syndr Gene Ther 2011; 2: 106.
11. Yin W, Carballo-Jane E, McLaren DG, Mendoza VH, Gagen K, Geoghagen NS et al. Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res 2011; 53: 51-65.
12. Morris MD, Fitch CD. Spontaneous hyperlipidemia in rhesus monkey. Biochem Med 1968; 2: 209-215.
13. Lee JA, Morris MD. Characterization of the serum low-density lipoproteins of normal and two rhesus monkeys with spontaneous hyperbeta-lipoproteinemia. Biochem Med 1974; 10: 245-257.
14. Hummel M, Li ZG, Pfaffinger D, Neven L, Scanu AM. Familial hypercholesterolemia in a rhesus monkey pedigree: molecular basis of low density lipoprotein receptor deficiency. Proc Natl Acad Sci USA 1990; 87: 3122-3126.
15. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009; 29: 431-438.
16. Scanu AM, Khalil A, Neven L, Tidore M, Dawson G, Pfaffinger D et al. Genetically determined hypercholesterolemia in a rhesus monkey family due to a deficiency of the LDL receptor. J Lipid Res 1988; 29: 1671-1681.
17. Brunetti-Pierri N, Stapleton GE, Law M, Breinholt J, Palmer DJ, Zuo Y et al. Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol Ther 2009; 17: 327-333.
18. Brunetti-Pierri N, Liou A, Patel P, Palmer D, Grove N, Finegold M et al. Balloon catheter delivery of helper-dependent adenoviral vector results in sustained, therapeutic hFIX Expression in rhesus macaques. Mol Ther 2012; 20: 1863-1870.
19. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 2004; 15: 35-46.
20. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
21. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 2008; 82: 546-554.
22. Kassim SH, Li H, Vandenberghe LH, Hinderer C, Bell P, Marchadier D et al. Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. PLoS One 2010; 5: e13424.
23. Chen SJ, Sanmiguel J, Lock M, McMenamin D, Draper C, Limberis MP et al. Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia. Hum Gene Ther Clin Dev 2013; 24: 154-160.
24. Brunetti-Pierri N, Stapleton GE, Palmer DJ, Zuo Y, Mane VP, Finegold MJ et al. Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into nonhuman primates for liver-directed gene therapy. Mol Ther 2007; 15: 732-740.
25. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-2365.
26. Perreau M, Kremer EJ. Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol 2005; 79: 14595-14605.
27. Calcedo R, Vandenberghe LH, Roy S, Somanathan S, Wang L, Wilson JM. Host immune responses to chronic adenovirus infections in human and nonhuman primates. J Virol 2009; 83: 2623-2631.
28. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin SW et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human-or chimpanzee-derived adenovirus vectors. J Virol 2007; 81: 6594-6604.
29. Shayakhmetov DM, Di Paolo NC, Mossman KL. Recognition of virus infection and innate host responses to viral gene therapy vectors. Mol Ther 2010; 18: 1422-1429.
30. Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK et al. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 2007; 15: 378-385.
31. Appledorn DM, Patial S, McBride A, Godbehere S, Van Rooijen N, Parameswaran N et al. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 2008; 181: 2134-2144.
32. VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: siteselective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol 2004; 24: 12-22.
33. Kassim SH, Li H, Bell P, Somanathan S, Lagor W, Jacobs F et al. Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. Hum Gene Ther 2013; 24: 19-26.
34. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50(Suppl): S172-S177.
35. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014; 63: 2531-2540.
36. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014; 63: 2541-2548.
37. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D et al. Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014; 311: 1870-1882.
38. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012; 380: 29-36.
39. Stein EA, Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep 2013; 15: 310-323.
40. Marais AD, Raal FJ, Stein EA, Rader DJ, Blasetto J, Palmer M et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 2008; 197: 400-406.
41. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-178.
42. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441: 111-114.
43. Koornneef A, Maczuga P, van Logtenstein R, Borel F, Blits B, Ritsema T et al. Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice. Mol Ther 2011; 19: 731-740.
44. Maczuga P, Verheij J, van der Loos C, van Logtenstein R, Hooijer G, Martier R et al. Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver. Gene Therapy 2014; 21: 60-70.
45. Palmer D, Ng P. Improved system for helper-dependent adenoviral vector production. Mol Ther 2003; 8: 846-852.
46. Li R, Paul A, Ko KW, Sheldon M, Rich BE, Terashima T et al. Interleukin-7 induces recruitment of monocytes/macrophages to endothelium. Eur Heart J 2012; 33: 3114-3123.
47. Leen AM, Sili U, Vanin EF, Jewell AM, Xie W, Vignali D et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood 2004; 104: 2432-2440.
48. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-1166.
49. Kushwaha RS, Barrett PH, Reardon CA, Lewis DS, Carey KD, Getz GS et al. Relationships of plasma and hepatic variables with rates of plasma low-density lipoprotein apolipoprotein B metabolism in baboons fed low-and high-fat diets. Metabolism 1995; 44: 1058-1066.